Treatment News

GTx Announces Symposium and Presentation of Scientific Poster Presentations on Enobosarm at the 2013 MASCC/ISOO International Symposium on Supportive Care in Cancer

2.6 from 8 votes
Tuesday, June 25, 2013

GTx, Inc. announced that at the upcoming 2013 MASCC/ISOO International Symposium on Supportive Care In Cancer in Berlin, Germany, the Company and its clinical collaborators are showcasing two poster presentations on enobosarm for the prevention and treatment of muscle wasting in cancer patients.

Additionally, the Company is sponsoring a symposium on Muscle Wasting in Non-Small Cell Lung Cancer Patients at 2:00 PM Central European Time on June 28, 2013.

MASCC/ISOO: InterContinental Convention Centre, Berlin, Germany

Sponsored Symposium: A Novel Agent for the Potential Prevention and Treatment of Muscle Wasting in Non-Small Cell Lung Cancer Patients

Location: Hall B

Time: Friday, June 28th 2:00 PM – 3:30 PM

Abstract # P2-028: Randomized Trials in NSCLC Investigating the Selective Androgen Receptor Modulator (SARM) Enobosarm to Prevent and Treat Muscle Wasting: Feasibility and Characteristics of Patients at Baseline.

Lead Author: J. Crawford

Abstract # P2-030: Improved Physical Functioning is Associated with Increased Lean Body Mass (LBM): Findings From a Phase II Trial of the Selective Receptor Modulator (SARM) Enobosarm.

Lead Author: J. Crawford

Abstracts will be presented at Poster Session 2, on Friday, June 28th, at 9:30 AM CET.

About GTx

GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions.

Denise Powell
Marc Hanover
Source: GTx, Inc.
2.6 from 8 votes
Free Newsletter
Trending News